tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: AVEO Pharma (AVEO), Neurocrine (NBIX) and Tandem Diabetes Care (TNDM)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on AVEO Pharma (AVEOResearch Report), Neurocrine (NBIXResearch Report) and Tandem Diabetes Care (TNDMResearch Report).

AVEO Pharma (AVEO)

Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on AVEO Pharma on August 5 and set a price target of $15.00. The company’s shares closed last Monday at $8.01, close to its 52-week high of $8.20.

According to TipRanks.com, Willey is a 5-star analyst with an average return of 16.1% and a 48.2% success rate. Willey covers the Healthcare sector, focusing on stocks such as Silverback Therapeutics, Inovio Pharmaceuticals, and Bolt Biotherapeutics.

AVEO Pharma has an analyst consensus of Strong Buy, with a price target consensus of $14.67, representing an 84.5% upside. In a report issued on July 27, SVB Securities also maintained a Buy rating on the stock with a $15.00 price target.

See today’s best-performing stocks on TipRanks >>

Neurocrine (NBIX)

In a report issued on August 5, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Neurocrine, with a price target of $138.00. The company’s shares closed last Monday at $104.59, close to its 52-week high of $108.02.

According to TipRanks.com, Matteis is a 4-star analyst with an average return of 9.1% and a 50.0% success rate. Matteis covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, KalVista Pharmaceuticals, and BioMarin Pharmaceutical.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Neurocrine with a $114.42 average price target, implying a 10.0% upside from current levels. In a report issued on July 29, Robert W. Baird also maintained a Buy rating on the stock with a $117.00 price target.

Tandem Diabetes Care (TNDM)

Stifel Nicolaus analyst Mathew Blackman maintained a Hold rating on Tandem Diabetes Care on August 5 and set a price target of $72.00. The company’s shares closed last Monday at $60.10, close to its 52-week low of $52.08.

According to TipRanks.com, Blackman is a 4-star analyst with an average return of 20.0% and a 54.1% success rate. Blackman covers the Healthcare sector, focusing on stocks such as Cardiovascular Systems, Apollo Endosurgery, and Alphatec Holdings.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Tandem Diabetes Care with a $95.56 average price target, representing a 58.0% upside. In a report issued on August 4, Robert W. Baird also maintained a Hold rating on the stock with a $76.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on AVEO:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More